Rhein inhibits transforming growth factor β1 induced plasminogen activator inhibitor-1 in endothelial cells

Chinese Medical Journal

Volumn 116, Issue 3, 2003, Pages 354-359

  Zhu, Jiaming ^a   Liu, Zhihong ^a   Huang, Haidong ^a   Chen, Zhaohong ^a   Li, Leishi ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Endothelial cells; Plasminogen activator inhibitor 1; Rhein

Indexed keywords

ANTHRAQUINONE DERIVATIVE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P42; PROTEIN P44; RHEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL LINE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NORTHERN BLOTTING; PROTEIN SYNTHESIS; UPREGULATION; VASCULAR DISEASE; WESTERN BLOTTING;

ANTHRAQUINONES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0037357562     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Goligorsky MS, Chen J, Brodsky S. Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 2001;37:744-748.
2. Cines DB, Pollak E, Buck CA, et al. Endothelial cell in physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527-3561.
3. Galajda P, Martinka E, Balaz, D, et al. Plasminogen activator inhibitor (PAI-1) and markers of endothelial dysfunction in patients with diabetes mellitus. Vnitr Lek 1997;43:744-747.
4. Petzelbauer E, Springhorn JP, Tucher AM, et al. Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cell migration by TGF-β1. Am J Pathol 1996;149:923-931.
5. Rerolle JP, Hertig A, Nguyen G, et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000;58:1841-1850.
6. Loskutoff DJ, Sawdey M, Keeton M, et al. Regulation of PAI-1 gene expression in vivo. Thromb Haemost 1993;70:135-137.
7. Yang JW, Li LS , Zhang Z. Experimental study of rhein treatment on diabetic nephropathy. Chin J Endocrinol Metab 1993;9:222-224.
8. Guo XH, Liu ZH, Dai CS, et al. Rhein inhibits renal tubular epithelial cell hypertrophy and extracellular matrix accumulation induced by transforming growth factor β1. Acta Pharmacol Sin 2001;22:934-938.
9. Zhu JM, Liu ZH, Li YJ, et al. Inhibition of glucose transporter 1 ovexpression in mesangial cells by rhein. Chin J Intern Med 2001;40:537-542.
10. Kim SB , Kang SA, Park JS, et al. Effects of hypoxia on the extracellular matrix production of cultured rat mesangial cells. Nephron 1996;72:275-280.
11. De Vriese AS, Verbeuren TJ, Vande-Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmcol 2000;130: 963-974.
12. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 2000;47:457-464.
13. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 1989;32:219-226.
14. Feldt-Rasmussen B. Microalbuminuria, endothelial dysfunction and cardiovascular risk. Diabetes Metab 2000; 26 (Suppl 4):64-66.
15. Bell D, Johns TE, Lopez LM. Endothelial dysfunction: implications for therapy of cardiovascular disease. Ann Pharmacother 1998;32:459-470.
16. Chen J, Brodsky S, Li H, et al. Delayed branching of endothelial capillary-like cords in glycated collagen I is mediated by early induction of PAI-1. Am J Physiol 2001;281:F71-80.
17. Kagami S, Kuhara T, Okada K, et al. Dual effects of angiotensin II on the plasminogen/plasmin system in the rat mesangial cells. Kidney Int 1997;51:664-671.
18. Kanalas JJ, Hopfer U. Effect of TGF-β1 and TNF-β on the plasminogen system of rat proximal tubular epithelial cells. J Am Soc Nephrol 1997;8:184-192.
19. Yamamoto T, Nakamura T, Noble NA, et al. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993;90:1814-1818.
20. Border WA, Noble NA. Transforming growth factor ( in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
21. Kagami S, Border WA, Miller DE, et al. Angiotensin II stimulates extracellular matrix portein synthesis through induction of transforming growth factor β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
22. Oda T, Kim H, Wing D, et al. Effects of genetic PAI-1 deficiency in mice with protein-overload proteinuria [abstract]. J Am Soc Nephrol 1999;10:A2928.
23. Hayashida T, Poncelet AC, Hubchak SC, et al. TGF-β1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int 1999;56:1710-1720.
24. Kutz SM, Hordines J, McKeown-Longo PJ, et al. TGF-beta1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci 2001;114:3905-3914.
25. Choi ME. Mechanism of transforming growth factor- singaling: role of the mitogen-activated protein kinase. Kidney Int 2000; 58:S53-S58.
26. Keeton MR, Curriden SA, Van-Zonneveld AJ, et al. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem 1991;266:23048-23052.
27. Liu ZH, Li YJ, Chen ZH, et al. Glucose transporter in human glomerular mesangial cells modulated by transforming growth factor-beta and rhein. Acta Pharmacol Sin 2001;22:169-175.
28. Border WA, Noble NA. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 1998;54: 1390-1391.